A Belfast-based clinical trial software specialist has received a £1 million loan from Innovate UK to help further develop its business.

Clinical trials

Exploristics will use the funding to develop the capabilities of its cloud-based data analytics platform for clinical trial design. The company’s Kerus Cloud platform provides a virtual environment for optimising clinical study design and data analysis. The system is designed to remove barriers to accessing cutting-edge clinical trial planning and is currently the only software that can simulate trials with multiple correlated outcomes. This enables it to make sense of the complex relationships between the many biological factors that can influence a study’s outcomes.

Exploristics hopes that the Kerus Cloud platform can help transform the speed and efficiency of bringing new medicines to market. The company will use the funding to further integrate Kerus Cloud into an intelligent software ecosystem.

The funding follows the appointment of Chris Molloy as Exploristics’ non-executive chairman.

“It’s an exciting time to be joining Exploristics as there is real need for optimised, data-driven clinical trial design, particularly as biopharmaceutical companies face the challenges presented by emerging research areas such as precision medicine.

“Kerus Cloud really addresses this need and I believe it will have a truly transformative effect on the industry. I look forward to working with the team to achieve this and drive forward the company’s growth,” Molloy said.

Dr Aiden Flynn, CEO of Exploristics added: “It’s a pleasure to welcome Chris to the team at such a key moment for the business and his leadership experience and industry knowledge will be central to supporting our growth strategy.

“Our next generation trial design software seeks to improve the quality of global clinical research and ultimately ensure that patients benefit from new drug therapies as quickly and efficiently as possible.

“This latest funding brings us another step closer to achieving that goal and help to revolutionise clinical trials across the globe.”